Maria Kourilovitch

Dr. Maria Kourilovitch

Centro de Reumatología y Enfermedades Autoinmunes, Corporación Médica Monte Sinai, Cuenca, Azuay, Ecuador
orcid
Centro de Reumatología UNERA, Corp.Médica Monte Sinai

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Journal of Autoimmunity
Verified
Journal Article
Closed access
MKMaria Kourilovitch
Maria Kourilovitch
CGClaudi Galarza-Maldonado
Claudi Galarza-Maldonado
EOEsteban Ortiz-Prado
Esteban Ortiz-Prado

1 February 2012 in Autoimmunity Reviews
Verified
Journal Article
Closed access
CGClaudi Galarza-Maldonado
Claudi Galarza-Maldonado
MKMaria Kourilovitch
Maria Kourilovitch
OPOscar M. Pérez-Fernández
Oscar M. Pérez-Fernández
MGMariana Gaybor
Mariana Gaybor
CCChristian Cordero
Christian Cordero
NSNikolai F. Soroka
Nikolai F. Soroka

26 June 2022 in Journal of Translational Autoimmunity
Verified
Journal Article
Open access
MKMaria Kourilovitch
Maria Kourilovitch
CGClaudio Galarza–Maldonado
Claudio Galarza–Maldonado
The complex pathological mechanisms of autoimmune diseases have now been discovered and described, including interactions between innate and adaptive immunity, the principal cells of which are neutrophils and lymphocytes. Neutrophil-to–lymphocyte ratio (NLR) was proposed as a biomarker for inflammation that reflects the balance between these aspects of the immune system. NLR is widely studied as a prognostic or screening parameter in quantity diseases with important inflammatory components such as malignancies, trauma, sepsis, critical care pathology, etc. Although there are still no consensually accepted normal values for this parameter, there is a proposal to consider an interval of 1–2 as a normal value, an interval of 2–3 as a grey area indicating subclinical inflammation and values above 3 as inflammation.

1 December 2010 in Autoimmunity Reviews
Verified
Journal Article
Closed access
CGClaudi Galarza-Maldonado
Claudi Galarza-Maldonado
MKMaria Kourilovitch
Maria Kourilovitch
JMJulio E. Molineros
Julio E. Molineros
MCMario H. Cardiel
Mario H. Cardiel
LZLuis Zurita
Luis Zurita
RCRicard Cervera
Ricard Cervera

6 March 2017 in Antibodies
Verified
Journal Article
Open access
PDF file
JBJessica Bravo-Barrera
Jessica Bravo-Barrera
MKMaria Kourilovitch
Maria Kourilovitch
CGClaudi Galarza-Maldonado
Claudi Galarza-Maldonado
Neutrophil extracellular traps (NETs) are a network of extracellular fibers, compounds of chromatin, neutrophil DNA and histones, which are covered with antimicrobial enzymes with granular components. Autophagy and the production of reactive oxygen species (ROS) by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase are essential in the formation of NETs. There is increasing evidence that suggests that autoantibodies against beta-2-glycoprotein-1 (B2GP1) induce NETs and enhance thrombosis. Past research on new mechanisms of thrombosis formation in antiphospholipid syndrome (APS) has elucidated the pharmacokinetics of the most common medication in the treatment of the disease.

1 March 2015 in Clinical Rheumatology
Verified
Journal Article
Open access
PDF file
VKVianna Khoury
Vianna Khoury
MKMaria Kourilovitch
Maria Kourilovitch
LMLoreto Massardo
Loreto Massardo
Patient education is highly recommended in rheumatoid arthritis (RA) to support patient management. The challenge is to adhere to the recommendations for providing health education to RA patients in Latin American and the Caribbean (LAC) countries taking into account factors such as patient health illiteracy, lack of rheumatologists, and lack of resources including access to disease-modifying antirheumatic drugs (DMARDs). As existing educational material in regional languages is not readily available and inadequate, we propose developing a web-based educational program that would fulfill the requirements of most patients with RA across LAC countries with an emphasis on the correct and safe use of methotrexate.